1. Document reveals scope of Operation Warp Speed and underscores vast military involvement — New data bolsters Sarepta gene therapies for two deadly muscle diseases — Inovio forced to delay planned phase 2/3 testing of COVID vaccine — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Will EpiPen play spoilsport in Mylan earnings?

Discussion in 'Mylan/Bertek' started by anonymous, Feb 28, 2018 at 11:14 AM.

  1. anonymous

    anonymous Guest

    There is a lot to look forward to as Mylan reports earnings aftermarket today. The stock has been up 9.65% since it reported last quarter results. Market pundits expect earnings to be lower this quarter, complemented by a sales decline of 0.80%.

    https://news.alphastreet.com/will-epipen-play-spoilsport-in-mylan-earnings/

    Analysts view lower EpiPen sales, which impacted third quarter results, to hinder the company’s earnings this time also. Meanwhile, the company had raised the lower end of its sales outlook for 2017, putting best hopes on the recently launched generic version of Copaxone.